Platelet transfusion refractoriness and anti-HLA immunization

被引：40

作者：

Blandin, Lucie ^{[1
]}

Douge, Aurore ^{[1
,2
]}

Fayard, Amandine ^{[3
]}

Bay, Jacques-Olivier ^{[3
,4
]}

Berlie, Guillaume ^{[5
]}

Pereira, Bruno ^{[6
]}

Lemal, Richard ^{[1
,4
]}

Rouzaire, Paul ^{[1
]}

机构：

[1] Clermont Ferrand Univ Hosp, Histocompatibil & Immunogenet Lab, 58 Rue Montalembert, F-63003 Clermont Ferrand, France

[2] Clermont Ferrand Univ Hosp, Oncol Dept, Clermont Ferrand, France

[3] Clermont Ferrand Univ Hosp, Clin Hematol Dept, Clermont Ferrand, France

[4] Clermont Auvergne Univ, CHELTER EA7453, Clermont Ferrand, France

[5] Etab Francais Sang Auvergne Rhone Alpes, Clermont Ferrand, France

[6] Clermont Ferrand Univ Hosp, DRCI, Biostat Unit, Clermont Ferrand, France

来源：

TRANSFUSION | 2021年 / 61卷 / 06期

关键词：

anti‐ HLA immunization; MFI threshold; platelet transfusion refractoriness;

D O I：

10.1111/trf.16358

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Platelet transfusion refractoriness (PTR), defined as an unsatisfactory post-transfusion platelet count increment, is a common complication of patients receiving multiple transfusions. Different strategies are described in the management of PTR. In this work, we demonstrate the efficacy of the detection and identification of anti-HLA antibodies in the recipient using a threshold of 3000 mean fluorescence intensity (MFI), and the seek of donors not expressing HLA antigens against which the patient is immunized.

引用

页码：1700 / 1704

页数：5

共 18 条

[1] Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness [J].

Basire, A. ;

Picard, C. .

TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2014, 21 (4-5) :193-206

[2] Clinical relevance of the HLA system in blood transfusion [J].

Brown, C. J. ;

Navarrete, C. V. .

VOX SANGUINIS, 2011, 101 (02) :93-105

[3]

Brubaker DB, 1998, AM J HEMATOL, V58, P165, DOI 10.1002/(SICI)1096-8652(199807)58:3<165::AID-AJH2>3.3.CO

[4]

2-X

[5] HLA-C expression on platelets: Studies with an HLA-Cw1-specific human monoclonal antibody [J].

Datema, G ;

Stein, S ;

Eijsink, C ;

Mulder, A ;

Claas, FHJ ;

Doxiadis, IIN .

VOX SANGUINIS, 2000, 79 (02) :108-111

[6]

DUQUESNOY RJ, 1977, TRANSPLANT P, V9, P1827

[7] Management of the Platelet Refractory Patient [J].

Forest, Stefanie K. ;

Hod, Eldad A. .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2016, 30 (03) :665-+

[8] Platelet transfusion refractoriness [J].

Hod, Eldad ;

Schwartz, Joseph .

BRITISH JOURNAL OF HAEMATOLOGY, 2008, 142 (03) :348-360

[9] HLA-selected platelets for platelet refractory patients with HLA antibodies: a single-center experience [J].

Karlstrom, Cecilia ;

Linjama, Tiina ;

Edgren, Gustaf ;

Lauronen, Jouni ;

Wikman, Agneta ;

Hoglund, Petter .

TRANSFUSION, 2019, 59 (03) :945-952

[10] Frequency and causes of refractoriness in multiply transfused patients [J].

Legler, TJ ;

Fischer, I ;

Dittmann, J ;

Simson, G ;

Lynen, R ;

Humpe, A ;

Riggert, J ;

Schleyer, E ;

Kern, W ;

Hiddemann, W ;

Kohler, M .

ANNALS OF HEMATOLOGY, 1997, 74 (04) :185-189

← 1 2 →